Diversity of cell phenotypes among MT-2 cell lines affects the growth of U937 cells and cytokine production

Nomura, Hajime; Umekita, Kunihiko; Hashikura, Yuuki; Umeki, Kazumi; Yamamoto, Ikuo; Aratake, Yatsuki; Saito, Mineki; Hasegawa, Hiroo; Yanagihara, Katsunori; Okayama, Akira

doi:10.1007/s13577-018-00231-3

Cited by 2 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We selected MT2 and TL-Om1 as HTLV-1-infected T-cell lines in this investigation. Diversity among MT2 cell lines was pointed out in a previous paper (Nomura et al, 2019). We therefore performed additional experiments using another type of HTLV-1-infected T-cell line, TL-Om1.…”

mentioning

confidence: 89%

In vitro Evaluation of the Safety of Adalimumab for the Eye Under HTLV-1 Infection Status: A Preliminary Study

et al. 2020

View full text Add to dashboard Cite

Adalimumab (ADA), a fully human monoclonal tumor necrosis factor (TNF)-α antibody, is one of the most widely used biologics in the treatment of inflammatory diseases. However, ADA can exacerbate infectious conditions, induce paradoxical reactions such as inflammation, and cause neoplasia. Human T-cell leukemia virus type 1 (HTLV-1) is an infectious agent that induces inflammation and neoplastic infiltration in the eye. To date, numerous HTLV-1 carriers have been treated with adalimumab to suppress inflammation out of necessity, when standard anti-inflammatory drugs such as steroids and immunosuppressive agents have proven inadequate to control the inflammation. Here, we clarify the safety of adalimumab for the eye under HTLV-1 infectious conditions in vitro. We used the adult retinal pigment epithelial cell line (ARPE)-19 cell line as ocular resident cells, and used MT2 and TL-Om1 as HTLV-1-infected cells. ARPE-19 and MT2/TL-Om1 were co-cultured, and then adalimumab was administered. Production of cytokines and chemokines, TNF-α receptor (TNF-R), HTLV-1 proviral load (PVL), and apoptosis were measured to assess the effects of adalimumab. Contact between ARPE-19 and MT2/TL-Om1 produced inflammatory cytokines such as TNF, interleukin (IL)-6, IL-8 and IL-10, and transduced chemokines such as interferon-inducible protein-10 (IP-10), monocyte chemotactic protein-1 (MCP-1), monokine induced by interferon-γ (MIG), and regulated on activation, normal T cell expressed and secreted (RANTES). No inflammatory cytokines and chemokines were exacerbated by adalimumab. Expression of TNF-R on ARPE-19 and MT2/TL-Om1 cells, HTLV-1 PVLs of MT2/TL-Om1 cells, and cell growth rate and apoptotic rate of ARPE-19 were unaffected by adalimumab. In conclusion, adalimumab does not appear to exacerbate HTLV-1-associated inflammatory conditions in the eye or increase PVL in HTLV-1-infected T cells. These data suggest that adalimumab could be used safely for the eye under HTLV-1 infectious conditions from the perspective of in vitro assessment.

show abstract

mentioning

confidence: 89%

In vitro Evaluation of the Safety of Adalimumab for the Eye Under HTLV-1 Infection Status: A Preliminary Study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It is possible that certain clones of HTLV-1-infected cells proliferate and alter both innate and acquired immunity of HTLV-1 carriers. Previous studies have suggested that the proinflammatory status of HTLV-1-infected cells is characterized by the presence of cytokines, such as TNF, IFN-γ, IL-6, IP-10, TGF, and GM-CSF [ 36 , 37 ]. Both the proliferation and cytokines production of RASFs was increased by coculture with these HTLV-1-infected cells [ 38 ].…”

Section: Htlv-1 Causes Inflammation In Vitromentioning

confidence: 99%

Effect of HTLV-1 Infection on the Clinical Course of Patients with Rheumatoid Arthritis

Umekita

2022

Viruses

Self Cite

View full text Add to dashboard Cite

Human T-cell leukemia virus type 1 (HTLV-1) is the causative agent of adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The effects of HTLV-1 on health are not fully elucidated. Epidemiological studies have shown that the prevalence of HTLV-1 infection is high in patients with rheumatic diseases. The prevalence of comorbidities, such as Sjögren’s syndrome and rheumatoid arthritis (RA), is higher in patients with HAM/TSP than the in general population. Studies have shown the effects of HTLV-1-infection on the clinical course of RA. Major questions on the association between HTLV-1 infection and RA: (1) Is it possible that HTLV-1 infection causes RA? (2) Do patients with RA who are infected with HTLV-1 have different clinical features? (3) Are immunosuppressants associated with an increased prevalence of HAM/TSP or ATL in RA patients with HTLV-1 infection? Is ATL an immunosuppressive therapy-associated lymphoproliferative disorder? No large-scale studies have investigated the incidence of ATL in patients with RA. However, several studies have reported the development of ATL in patients with RA who have HTLV-1 infection. This review aimed to shed light on the association between HTLV-1 infection and RA and summarize the unmet medical needs of RA patients with HTLV-1 infection.

show abstract

Diversity of cell phenotypes among MT-2 cell lines affects the growth of U937 cells and cytokine production

Cited by 2 publications

References 32 publications

In vitro Evaluation of the Safety of Adalimumab for the Eye Under HTLV-1 Infection Status: A Preliminary Study

In vitro Evaluation of the Safety of Adalimumab for the Eye Under HTLV-1 Infection Status: A Preliminary Study

Effect of HTLV-1 Infection on the Clinical Course of Patients with Rheumatoid Arthritis

Contact Info

Product

Resources

About